Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: The role of antifungal susceptibility testing

Clinical Infectious Diseases

Volumn 22, Issue 2, 1996, Pages 322-328

  Witt, Mallory D ^a   Lewis, Roger J ^b   Larsen, Robert A ^b   Milefchik, Eric N ^b   Leal, Mary Ann E ^b   Haubrich, Richard H ^b   Richie, John A ^b   Edwards Jr , John E ^b   Ghannoum, Mahmoud A ^b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; FLUCYTOSINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FUNGAL MENINGITIS; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030043279     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/22.2.322     Document Type: Article

References (29)

1. Dismukes WE. Cryptococcal meningitis in patients with AIDS. J Infect Dis 1988;157:624-8.
2. Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 1989;321: 794-9.
3. Kovacs JA, Kovacs AA, Polis M, et al. Cryptococcosis in the acquired immunodeficiency syndrome. Ann Intern Med 1985;103:533-8.
4. Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979;301:126-31.
5. Dismukes WE, Cloud G, Gallis HA, et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987;317:334-41.
6. Zuger A, Louie E, Holzman RS, Simberkoff MS, Rahal JJ. Cryptococcal disease in patients with the acquired immunodeficiency syndrome: diagnostic features and outcome of treatment. Ann Intern Med 1986;104:234-40.
7. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992;326:83-9.
8. Palou de Fernandez E, Patino MM, Graybill JR, Tarbit MH. Treatment of cryptococcal meningitis in mice with fluconazole. J Antimicrob Chemother 1986;18:261-70.
9. Stern JJ, Hartman BJ, Sharkey P, et al. Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients. Am J Med 1988;85:477-80.
10. Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined with fiucytosine for cryptococcal meningitis in persons with AIDS. Clin Infect Dis 1994;19:741-5.
11. Perfect JR. Fluconazole therapy for experimental cryptococcosis and candidiasis in the rabbit. Rev Infect Dis 1990;12(suppl 3):S299-302.
12. Arndt CAS, Walsh TJ, McCuIIy CL, Balis FM, Pizzo PA, Poplack DG. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J Infect Dis 1988;157:178-180.
13. Larsen RA, Leal MA, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. Ann Intern Med 1990;113:183-7.
14. Haubrich RH, Haghighat D, Bozzette SA, Tilles J, McCutchen JA, the California Collaborative Treatment Group. High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. J Infect Dis 1994;170:238-42.
15. White M, Cirrincione C, Blevins A, Armstrong D. Cryptococcal meningitis: outcome in patients with AIDS and patients with neoplastic disease. J Infect Dis 1992;165:960-3.
16. Clark RA, Greer D, Atkinson W, Valainis GT, Hyslop N. Spectrum of Cryptococcus neoformans infection in 68 patients infected with human immunodeficiency virus. Rev Infect Dis 1990;12:768-77.
17. Ghannoum MA, Ibrahim AS, Fu Y, Shafiq MC, Edwards JE, Criddle RS. Susceptibility testing of Cryptococcus neoformans: a microdilution technique. J Clin Microbiol 1992;30:2881-6.
18. Milefchik E, Leal M, Haubrich R, See R, Bozzette S, Larsen R. High dose fluconazole with and without flucytosine for AIDS associated cryptococcal meningitis [abstract WS-B5-12]. In: Programs and Abstracts of the 9th International Conference on AIDS/4th STD World Congress (Berlin). London: Wellcome Foundation, 1993.
19. SAS Institute, Inc. SAS/STAT user's guide, version 6.4th ed, vol 1. Cary, North Carolina: SAS Institute, 1989.
20. SAS Institute, Inc. SAS/STAT user's guide, version 6.4th ed, vol 2. Cary, North Carolina: SAS Institute, 1989.
21. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons, 1989.
22. Sugar AM, Stern JJ, Dupont B. Overview: treatment of cryptococcal meningitis. Rev Infect Dis 1990;12(suppl 3):S338-48.
23. Velez JD, Allendorfer R, Luther M, Rinaldi MG, Graybill JR. Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J Infect Dis 1993;168:508-10.
24. Rex JH, Pfaller MA, Rinaldi MG, Polak A, Galgiani JN. Antifungal susceptibility testing. Clin Microbiol Rev 1993;6:367-81.
25. Sheehan DJ, Espinel-Ingroff A, Moore LS, Webb CD. Antifungal susceptibility testing of yeasts: a brief overview. Clin Infect Dis 1993;17(suppl 2):S494-500.
26. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts: proposed standard. Document M27-P. Villanova, Pennsylvania: National Committee for Clinical Laboratory Standards, 1992.
27. Diamond RD, Bennett JE. Prognostic factors in cryptococcal meningitis: a study in 111 cases. Ann Intern Med 1974;80:176-81.
28. Peetermans W, Bobbaers H, Verhaegen J, Vandepitte J. Fluconazole-resistant Cryptococcus neoformans var gattii in an AIDS patient. Acta Clinica Belg 1993;48:405-9.
29. Casadevall A, Spitzer ED, Webb CD, Rinaldi MG. Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole. Antimicrob Agents Chemother 1993;37:1383-6.